Carl Salzman removes the stigma from the much aligned benzo, reminding us of when they are essential to treatment and when they cause harm. Dr. Salzman is the past chairman of the American Psychiatric Association’s Benzodiazepine Task Force.CME: Podcast CME Post-Tests are available using this subscription (https://www.thecarlatreport.com/product/carlat-psychiatry-podcast-cme-subscription/). If you have already enrolled in that program, please log in (https://www.thecarlatreport.com/my-account/).Published On: 07/18/2022Duration: 22 minutes, 06 secondsReferenced Article: “Benzodiazepines: A Reevaluation of Their Benefits and Dangers (https://www.thecarlatreport.com/the-carlat-psychiatry-report/benzodiazepines-reevaluation-benefits-dangers/),” The Carlat Child Psychiatry Report, June 2022 Chris Aiken, MD, Kellie Newsome, PMHNP, and Carl Salzman, MD have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Id. d’épisode : 1000570301788

GUID : http://www.blubrry.com/the_carlat_psychiatry_podcast/87722734/to-benzo-or-not-to-benzo-an-interview-with-carl-salzman/

Date de publication : 18/7/2022 à 08:00:00